In vivo gold standard for the ante-mortem assessment of brain β-amyloid pathology is
currently β-amyloid positron emission tomography or cerebrospinal fluid measures of β …

Introduction Convenient, cost‐effective tests for amyloid beta (Aβ) are needed to identify
those at higher risk for developing Alzheimer's disease (AD). This systematic review …

Alzheimer's disease (AD) is a common cause of dementia, characterised by cerebral
amyloid-β deposition, pathological tau and neurodegeneration. The prodromal stage of AD …

Background PET can be used for amyloid-tau-neurodegeneration (ATN) classification in
Alzheimer disease, but incurs considerable cost and exposure to ionizing radiation. MRI …

Background Considering the limited accessibility of amyloid position emission tomography
(PET) in patients with dementia, we proposed a deep learning (DL)-based amyloid PET …

Amyloid positivity is an early indicator of Alzheimer's disease and is necessary to determine
the disease. In this study, a deep generative model is utilized to predict the amyloid positivity …

Alzheimer's Disease (AD) is the leading cause of dementia and impairment in various
domains. Recent AD studies,(ie, Alzheimer's Disease Neuroimaging Initiative (ADNI) study) …

Purpose The pathological hallmarks of Alzheimer's disease (AD), amyloid, tau, and
associated neurodegeneration, are present in the cortical gray matter (GM) years before …

Abnormal β-amyloid (Aβ) accumulation in the brain is an early indicator of Alzheimer's
disease (AD) and is typically assessed through invasive procedures such as PET (positron …

Simple Summary Brain metastases (BMs) are cancerous lesions that originated from
cancers outside the brain. Specific types of BMs are found distributing in specific brain …